Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nab-Paclitaxel + carboplatin plus necitumumab in stage IV squamous NSCLC (phase 2, single-arm)
2016-002071-96Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of necitumumab in Pulmonary squamous cell carcinoma, sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate (ORR). Started Aug 2016; status: completed.
02
Drugs
necitumumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2016-002071-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002071-96.